Nine months ended
September 30,
2008 2007
Revenue:
Management fees $- $-
Grants 32,006 -
Royalty-related party - -
Total revenue 32,006 -
Expenses:
Research and development 14,798,173 21,722,174
Contracted research and
development-related party - -
Selling, general and administrative 5,237,579 5,362,769
Total expenses 20,035,752 27,084,943
Loss from operations (20,003,746) (27,084,943)
Net other (income) expense:
Interest income (284,330) (638,396)
Interest expense 310,296 350,268
Gain on sale of interest in Sarawak
Medichem Pharmaceuticals joint
venture - -
Net other (income) expense 25,966 (288,128)
Net loss (20,029,712) (26,796,815)
Less accumulated preferred stock
dividends of subsidiary for the
period 131,250 131,250
Net loss available to common
shareholders $(20,160,962) $(26,928,065)
Net loss per share available to
common shareholders - basic and
diluted $(0.52) $(0.95)
Weighted average shares outstanding -
basic and diluted
'/>"/>
SOURCE Advanced Life Sciences Holdings, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 Related biology technology :1.
Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients2.
Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter3.
Advanced Cell Technology Announces Proposed Financing4.
YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER5.
Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry6.
Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference7.
CeloNova BioSciences Announces Worlds First Line of Fully Color-Coded Embolic Particles at CIRSE: Embozene(TM) Color-Advanced Microspheres8.
Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology9.
Advanced Bionics Deploys CEVA-TeakLite(TM) DSP Core to Enhance Its Harmony(TM) HiResolution(R) Bionic Ear System10.
NIH Announces Advanced Cell Technologys Single Cell Embryo Biopsy Technique as a Means to Derive Embryonic Stem Cells to be Considered for Federal Funding11.
Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer